PMID- 33317670
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1815-7920 (Electronic)
IS  - 1027-3719 (Linking)
VI  - 24
IP  - 12
DP  - 2020 Dec 1
TI  - New TB drugs for the treatment of children and adolescents with 
      rifampicin-resistant TB in Mumbai, India.
PG  - 1265-1271
LID - 10.5588/ijtld.20.0165 [doi]
AB  - SETTING: Medecins Sans Frontieres (MSF) clinic in Mumbai, India.OBJECTIVE: To 
      determine the final treatment outcomes, culture conversion and adverse events 
      (AEs) during treatment among children and adolescents (0-19 years) with 
      rifampicin-resistant tuberculosis (RR-TB) who received ambulatory injectable-free 
      treatment, including bedaquiline (BDQ) and/or delamanid (DLM) during September 
      2014-January 2020.DESIGN: This was a retrospective cohort study based on review 
      of routinely collected programme data.RESULTS: Twenty-four patients were 
      included; the median age was 15.5 years (min-max 3-19) and 15 (63%) were females. 
      None were HIV-coinfected. All had fluoroquinolone resistance. Twelve received 
      treatment, including BDQ and DLM, 11 received DLM and one BDQ. The median 
      exposure to BDQ (n = 13) and DLM (n = 23) was 82 (IQR 80-93) and 82 (IQR 77-96) 
      weeks, respectively. Seventeen (94%) patients with positive culture at baseline 
      (n = 18) had negative culture during treatment; median time for 
      culture-conversion was 7 weeks (IQR 5-11). Twenty-three (96%) had successful 
      treatment outcomes: cured (n = 16) or completed treatment (n = 7); one died. 
      Eleven (46%) had 17 episodes of AEs. Two of 12 serious AEs were associated with 
      new drugs (QTcF >500 ms).CONCLUSION: Based on one of the largest global cohorts 
      of children and adolescents to receive new TB drugs, this study has shown that 
      injectable-free regimens containing BDQ and/or DLM on ambulatory basis were 
      effective and well-tolerated among children and adolescents and should be made 
      routinely accessible to these vulnerable groups.
FAU - Das, M
AU  - Das M
AD  - Medecins Sans Frontieres, Mumbai, Tata Institute of Social Sciences, Mumbai.
FAU - Mamnoon, F
AU  - Mamnoon F
AD  - Medecins Sans Frontieres, Mumbai.
FAU - Mansoor, H
AU  - Mansoor H
AD  - Medecins Sans Frontieres, Mumbai.
FAU - Meneguim, A C
AU  - Meneguim AC
AD  - Medecins Sans Frontieres, Mumbai.
FAU - Singh, P
AU  - Singh P
AD  - Medecins Sans Frontieres, Mumbai.
FAU - Shah, I
AU  - Shah I
AD  - Bai Jerbai Wadia Hospital for Children, Mumbai, India.
FAU - Ravi, S
AU  - Ravi S
AD  - Medecins Sans Frontieres, Mumbai.
FAU - Kalon, S
AU  - Kalon S
AD  - Medecins Sans Frontieres, Mumbai.
FAU - Hossain, F N
AU  - Hossain FN
AD  - Medecins Sans Frontieres, Mumbai.
FAU - Ferlazzo, G
AU  - Ferlazzo G
AD  - Southern Africa Medical Unit, Medecins Sans Frontieres, Cape Town, South Africa.
FAU - Isaakidis, P
AU  - Isaakidis P
AD  - Southern Africa Medical Unit, Medecins Sans Frontieres, Cape Town, South Africa.
FAU - Furin, J
AU  - Furin J
AD  - Department of Global Health and Social Medicine, Harvard Medical School, Boston, 
      MA, USA.
FAU - Acharya, S
AU  - Acharya S
AD  - Mumbai Districts AIDS Control Society, Mumbai.
FAU - Thakur, H P
AU  - Thakur HP
AD  - Tata Institute of Social Sciences, Mumbai, National Institute of Health and 
      Family Welfare, New Delhi, India.
LA  - eng
PT  - Journal Article
PL  - France
TA  - Int J Tuberc Lung Dis
JT  - The international journal of tuberculosis and lung disease : the official journal 
      of the International Union against Tuberculosis and Lung Disease
JID - 9706389
RN  - 0 (Antitubercular Agents)
RN  - 0 (Pharmaceutical Preparations)
RN  - VJT6J7R4TR (Rifampin)
SB  - IM
MH  - Adolescent
MH  - Antitubercular Agents/adverse effects
MH  - Child
MH  - Female
MH  - Humans
MH  - India
MH  - Male
MH  - *Pharmaceutical Preparations
MH  - Retrospective Studies
MH  - Rifampin/adverse effects
MH  - *Tuberculosis, Multidrug-Resistant/drug therapy
EDAT- 2020/12/16 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/12/15 05:42
PHST- 2020/12/15 05:42 [entrez]
PHST- 2020/12/16 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
AID - 10.5588/ijtld.20.0165 [doi]
PST - ppublish
SO  - Int J Tuberc Lung Dis. 2020 Dec 1;24(12):1265-1271. doi: 10.5588/ijtld.20.0165.